EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV ( ANRS CO4 ‐ FHDH )

S Abgrall iD, H Selinger-Leneman, E Lanoy, A Becker, S Matheron, P de Truchis, J Pavie, A Canestri, M A Khuong, D Rey, F Caby, P Tattevin und 3 weitere

HIV Medicine · 2025

DOI: 10.1111/hiv.13729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2025. Verfasst von S Abgrall und 14 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP, Hôpital Béclère, Service de Médecine Interne, Clamart, and Université Paris-Saclay, CESP INSERM U1018, Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: HIV Infections, Transients and Migrants, Viral Load, Anti-Retroviral Agents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ANRS-MIE, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Assessing the potential increased risk of viral rebound (VR) in migrants requires adequate control for sex and acquisition risk groups.

Methods

People living with HIV1, enrolled in the ANRS CO4‐French Hospital Database on HIV, who achieved virological suppression with antiretroviral therapy (ART) initiated between 2006 and 2016 were included. We first compared the risk of VR, with loss to follow‐up and death considered as competing events, across origin among the HIV acquisition groups, then across acquisition groups among the different origins, and finally across modality of a variable combining sex, acquisition group, and origin. Models were adjusted for clinical and biological confounding factors.

Results

We included 21 571 French natives (FRA), 10 148 migrants from sub‐Saharan Africa (SSA), 1137 migrants from the non‐French West Indies (NFWI), and 4205 other migrants (OTHER). The 5‐year probability of VR was 19% (95% confidence interval [CI] 19–20) overall, 15% in FRA, 21% in OTHER, 26% in SSA, and 34% in NFWI ( p < 0.0001). It was 14% in men who have sex with men (MSM), 23% in heterosexual men, and 23% in women ( p < 0.0001). After adjustment, all acquisition groups had a higher risk of VR than MSM from FRA, with men and women from NFWI having the highest risk (adjusted hazard ratio [aHR] 2.46; 95% CI 2.12–2.86 and aHR 2.59; 95% CI 2.20–3.04, respectively). Within each acquisition group, all groups of origin had a higher risk of VR than FRA. Within each region of origin, except the NFWI, heterosexual men had a higher risk of VR than MSM.

Conclusions

After accounting for sex and acquisition group, migration, especially from NFWI, remains prognostic of VR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsTransients and MigrantsViral LoadAnti-Retroviral AgentsHIV-1Anti-HIV AgentsHumansMaleFranceFemaleAdultMiddle AgedDatabases, FactualAfrica South of the Sahara

Stichwörter der Autor:innen

HIVgeographical originheterosexualmigrantvirological rebound

Substanzen

Anti-Retroviral AgentsAnti-HIV Agents

Autor:innen und Institutionen

  • AP-HP, Hôpital Béclère, Service de Médecine Interne, Clamart, and Université Paris-Saclay, CESP INSERM U1018, Le Kremlin-Bicêtre, France.
  • Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
  • Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France.
  • AP-HP, Hôpital Bichat-Claude Bernard, GHU Paris Nord, Paris, France.
  • AP-HP Hôpital Raymond Poincaré, Université Paris-Saclay, Garches, France.
  • AP-HP, Hôtel-Dieu, Paris, France.

ORCID-Profile: S Abgrall, S Grabar

Förderung

  • ANRS-MIE
  • Institut National de la Santé et de la Recherche Médicale
  • Sorbonne Université
  • the French Ministry of Health

Zitieren

APA

Abgrall, S., Selinger-Leneman, H., Lanoy, E., Becker, A., Matheron, S., de Truchis, P., Pavie, J., Canestri, A., Khuong, M. A., Rey, D., Caby, F., Tattevin, P., Palich, R., Grabar, S., & ANRS CO4‐FHDH (2025). Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV ( ANRS CO4 ‐ FHDH ). HIV Medicine. https://doi.org/10.1111/hiv.13729

Vancouver

Abgrall S, Selinger-Leneman H, Lanoy E, Becker A, Matheron S, de Truchis P, et al. Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV ( ANRS CO4 ‐ FHDH ). HIV Medicine. 2025. doi:10.1111/hiv.13729

BibTeX
@article{Abgrall2025,
  author = {Abgrall, S and Selinger-Leneman, H and Lanoy, E and Becker, A and Matheron, S and de Truchis, P and Pavie, J and Canestri, A and Khuong, M A and Rey, D and Caby, F and Tattevin, P and Palich, R and Grabar, S and ANRS CO4‐FHDH, ANRS CO4‐FHDH},
  title = {Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV ( ANRS CO4 ‐ FHDH )},
  journal = {HIV Medicine},
  year = {2025},
  doi = {10.1111/hiv.13729}
}
Kostenlos starten →